Comparative Pharmacology
Head-to-head clinical analysis: ASTRAMORPH PF versus DALGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTRAMORPH PF versus DALGAN.
ASTRAMORPH PF vs DALGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic